Selank and semax

The Soviet neuroscience establishment developed two metabolically stabilized peptides in the 1980s that still dominate Russian pharmacies but have never crossed the regulatory threshold in the West. Selank and Semax emerge from the same research lineage — both are shortened, stabilized analogs of endogenous regulatory peptides — but their mechanisms diverge sharply enough that treating them as interchangeable misses the evidence.

Two Peptides, Two Parent Molecules: Tuftsin-Derived Selank and ACTH-Fragment Semax

Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as a synthetic analog of tuftsin, a naturally occurring tetrapeptide cleaved from immunoglobulin G. Tuftsin itself regulates immune cell activity, particularly in phagocytes, but degrades rapidly in serum. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences extended the sequence and modified key residues to create a compound with a longer half-life and central nervous system activity. Selank's molecular weight is 751.86 Da.

Semax is also a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), derived from a fragment of adrenocorticotropic hormone (ACTH 4-10). ACTH is released by the pituitary gland and primarily drives cortisol synthesis in the adrenal cortex, but early peptide mapping studies showed that ACTH fragments lacking the full sequence still retained some behavioral effects in animal models. Semax was engineered to isolate those effects while eliminating the hormonal activity. Its molecular weight is 813.94 Da. It was approved for clinical use in Russia in 1996 for stroke recovery and cognitive disorders.

Both compounds were designed to resist enzymatic breakdown that limits the activity of their parent molecules. Both have been studied almost exclusively in Russian institutions. Both are available as nasal sprays in Russia and online from research peptide suppliers. The structural and mechanistic differences between them matter more than their shared origin story.

GABAergic Modulation in Selank, BDNF Upregulation in Semax: Distinct Signaling Pathways

Selank's most studied mechanism involves the GABAergic system. GABA is the brain's primary inhibitory neurotransmitter, and its receptor subtypes — particularly GABA-A — are molecular targets of benzodiazepines and related anxiolytics. A 2016 study in Frontiers in Neuroscience using receptor binding assays in rat brain tissue found that Selank modulated GABA-A receptor expression in the hippocampus and prefrontal cortex, increasing receptor density without directly binding as an agonist. This suggests an allosteric or upstream regulatory effect, distinct from the direct receptor activation seen with benzodiazepines. The same study noted increases in BDNF mRNA in treated animals, though the effect size was smaller than that reported for Semax.

Selank also interacts with enkephalin-degrading enzymes. A 2009 study published in Neuroscience and Behavioral Physiology demonstrated that Selank inhibited neutral endopeptidase and aminopeptidase N in vitro, both of which break down enkephalins — endogenous opioid peptides involved in pain and stress regulation. By slowing their degradation, Selank may prolong the signaling of these peptides without directly activating opioid receptors. This is mechanistically different from opioid agonists and may explain why the compound does not produce sedation or dependence in rodent models.

Semax operates through a different set of pathways. The peptide's most well-characterized mechanism is upregulation of brain-derived neurotrophic factor (BDNF). A 2006 study in the Journal of Neurochemistry demonstrated that Semax binds specifically to rat basal forebrain tissue and induces dose-dependent increases in BDNF mRNA and protein levels in the hippocampus. BDNF is critical for synaptic plasticity, neuronal survival, and learning. This mechanism is shared by antidepressants and physical exercise, both of which also raise BDNF over time.

Semax also modulates dopaminergic and serotonergic tone. A 2014 study in Neurochemical Journal using microdialysis in freely moving rats showed that Semax increased extracellular dopamine and serotonin concentrations in the striatum within 30 minutes of intranasal administration. The effect was transient and did not deplete monoamine stores, suggesting enhanced release rather than reuptake inhibition. More recent work from 2020 in Molecular Neurobiology identified Semax binding to the mu-opioid receptor, though with lower affinity than classic opioid ligands. The functional consequence of this binding is unclear, but it may contribute to the peptide's effects on stress response and neuroprotection.

Neither peptide crosses the blood-brain barrier efficiently when administered systemically. Both are typically delivered intranasally in research settings, which allows direct transport along olfactory nerve pathways into the central nervous system. Intranasal delivery in rodents produces measurable brain tissue concentrations within 15-30 minutes.

What Russian Clinical Studies Show — and What Western Replication Has Not Confirmed

The majority of clinical data on Selank and Semax comes from Russian institutions, and much of it has not been independently replicated in Western peer-reviewed trials. This does not mean the data is fabricated, but it does mean the evidence base is narrower than it appears.

For Selank, the largest published human study is a 2009 open-label trial in Human Psychopharmacology involving 60 patients with generalized anxiety disorder. Participants received intranasal Selank (3 mg per day, split into three doses) for 14 days. The Hamilton Anxiety Rating Scale (HAM-A) scores decreased by an average of 42% in the Selank group compared to 24% in the placebo group. No serious adverse events were reported, though 8% of participants experienced mild nasal irritation. The study was not blinded, and the placebo effect in anxiety trials is known to be substantial. A follow-up study in 2013 published in Neuroscience and Behavioral Physiology found similar anxiety reductions in a smaller sample (n=32) using a randomized, double-blind design, though dropout rates were not clearly reported.

Cell culture and rodent data support an anxiolytic mechanism. A 2015 study in Behavioural Brain Research showed that Selank-treated mice spent significantly more time in the open arms of an elevated plus maze (a standard anxiety test) compared to saline controls. The effect was blocked by a GABA-A antagonist, supporting the GABAergic mechanism. Another study in 2017 in Bulletin of Experimental Biology and Medicine found that Selank reduced corticosterone levels in stressed rats, suggesting a blunting of the hypothalamic-pituitary-adrenal (HPA) axis response.

For Semax, the strongest human evidence comes from stroke recovery studies. A 1999 randomized controlled trial published in Stroke enrolled 120 patients with acute ischemic stroke and assigned them to receive either Semax (intranasal, 12 mg per day for 10 days) or standard care. Neurological outcomes measured by the National Institutes of Health Stroke Scale (NIHSS) improved more rapidly in the Semax group, with statistically significant differences at 30 days. A 2005 follow-up study in Cerebrovascular Diseases replicated these findings in 200 patients, though both studies were conducted in Russian hospitals and have not been repeated in multicenter trials outside the region.

Rodent data on neuroprotection is more extensive. A 2007 study in Neurochemical Research using a middle cerebral artery occlusion model (the standard rodent stroke model) found that Semax reduced infarct volume by approximately 30% when administered within three hours of occlusion. Histological analysis showed reduced neuronal death in the penumbra. A 2012 study in Acta Naturae demonstrated that Semax upregulated genes involved in angiogenesis and immune regulation in ischemic brain tissue, including vascular endothelial growth factor (VEGF) and interleukin-10.

For cognitive enhancement, the human data is thinner. A 2010 open-label study in 24 healthy adults published in Bulletin of Experimental Biology and Medicine reported improved attention and working memory scores after 14 days of intranasal Semax (600 mcg twice daily). The study used validated neuropsychological tests, but there was no placebo control. Rodent studies consistently show improvements in spatial learning tasks. A 2013 study in Behavioural Brain Research found that Semax-treated rats learned a Morris water maze task faster than controls, and the effect persisted when retested two weeks after treatment ended.

These compounds are used for research purposes only and are not approved for human use outside Russia.

Dosing Ranges, Delivery Routes, and Stability Considerations from Published Research

Published human studies on Selank have used intranasal doses ranging from 600 mcg to 3 mg per day, typically divided into two or three administrations. The most common protocol is 900 mcg per day (300 mcg three times daily) for 10-14 days. Intranasal delivery is the standard route because systemic bioavailability is negligible due to rapid enzymatic degradation in serum. One pharmacokinetic study in rats published in 2011 in Pharmaceutical Chemistry Journal found that intranasal Selank produced measurable brain concentrations within 20 minutes, peaking at 45 minutes, with a terminal half-life of approximately 1.5 hours. Subcutaneous administration produced lower brain concentrations despite higher serum levels, supporting the rationale for nasal delivery.

Selank is unstable in aqueous solution at room temperature. A 2016 stability study in Pharmaceutical Chemistry Journal found that Selank degraded by more than 30% after 7 days at 25°C in phosphate-buffered saline. Refrigeration at 4°C extended stability to approximately 30 days. Lyophilized powder stored at -20°C remained stable for at least 12 months. Reconstituted solutions should be used within two weeks if refrigerated.

For Semax, intranasal doses in clinical trials have ranged from 600 mcg to 12 mg per day depending on the indication. Stroke studies used higher doses (6-12 mg per day), while cognitive enhancement studies used lower doses (600-1200 mcg per day). A 2014 pharmacokinetic study in healthy volunteers published in Drug Metabolism and Pharmacokinetics found that intranasal Semax (1 mg) produced peak plasma concentrations at 30 minutes, with a half-life of approximately 1 hour. Brain tissue concentrations in rats peak at similar times and decline with a longer half-life (2-3 hours), suggesting CNS retention.

Semax stability is somewhat better than Selank's. A 2018 study in Molecules found that Semax in phosphate-buffered saline at pH 7 retained 90% potency for 14 days at 4°C. Lyophilized powder stored at -20°C showed no detectable degradation over 24 months. Both peptides are sensitive to freeze-thaw cycles; repeated freezing reduces potency.

Neither peptide has been studied in combination with other CNS-active drugs in controlled human trials, but rodent data suggests potential interactions. A 2012 study in Bulletin of Experimental Biology and Medicine found that Selank potentiated the sedative effects of diazepam in mice, reducing the time to sleep onset by approximately 25%. This is consistent with GABAergic modulation. Semax has not shown similar potentiation with monoaminergic drugs in animal models, but the lack of data means interactions cannot be ruled out.

FAQ

Q: Are Selank and Semax bioequivalent or interchangeable?

No. They derive from different parent molecules, target different neurotransmitter systems, and produce different behavioral effects in animal models. Selank modulates GABAergic signaling and has primarily anxiolytic properties. Semax upregulates BDNF and modulates dopamine/serotonin, with stronger evidence for neuroprotection and cognitive enhancement. Using them interchangeably ignores the mechanistic and functional differences.

Q: Why hasn't either peptide been approved in the United States or Europe?

Approval requires large-scale, multicenter, placebo-controlled trials conducted to regulatory standards. Most published studies on Selank and Semax come from Russian institutions and do not meet FDA or EMA standards for drug approval. No Western pharmaceutical company has sponsored the necessary trials, likely because both peptides are unpatentable. Regulatory approval outside Russia would require tens of millions of dollars in clinical trial costs with no exclusivity period to recoup investment.

Q: What is the safety profile in humans based on existing data?

Published human studies report low rates of adverse events, primarily mild nasal irritation with intranasal delivery. No serious adverse events or deaths have been reported in the clinical literature. However, long-term safety data (beyond 6 months of continuous use) does not exist, and the total number of participants across all published trials is fewer than 500 for Selank and fewer than 1000 for Semax. Chronic use outside clinical supervision carries unknown risks.

Q: Can either peptide be taken orally?

No. Both are rapidly degraded by peptidases in the gastrointestinal tract, and oral bioavailability is effectively zero. Intranasal delivery is the only route that has produced measurable effects in published research. Subcutaneous injection produces higher serum concentrations but lower brain concentrations compared to intranasal delivery, making it a less efficient route for CNS effects.

Q: What is the evidence quality for cognitive enhancement?

For Semax, there is one small uncontrolled human study and consistent rodent data showing improved spatial learning and memory consolidation. For Selank, the cognitive data is weaker — mostly indirect effects through anxiety reduction. Neither has been tested in large, well-controlled trials specifically designed to measure cognitive outcomes in healthy adults. The strongest evidence for Semax is in stroke recovery, not in cognitive enhancement in healthy individuals.

---

The information provided here is for educational and research purposes only. Selank and Semax are not approved by the FDA or EMA for human use, and their long-term safety in humans has not been established through Western regulatory standards. This content does not constitute medical advice, and anyone considering these compounds should consult a qualified healthcare provider.